Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer

Study ID
NCT01713218

Study type
Interventional

Study phase
Early Phase 1

Study status
Unknown status

Trial Acronym

NEOPACHI-001

Trial Summary

Pancreatic ductal adenocarcinoma (PDAC) has one of the worst prognoses of all human cancers and is considered as a sanctuary, resistant to most of the drugs used. Identification of new molecular targets involved in its pathogenesis is urgently needed and required both proper and innovative efficacy assessment. This proof-of-concept trial is studying the "dynamic" tumor response after the administration of a short course (4 weeks) neoadjuvant combination of gemcitabine and a Hedgehog inhibitor (Vismodegib) before surgery in patients with operable pancreatic cancer.

More informations

Trial Starting Date

Dec 31,2012

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit